Title: Trough Concentrations of Infliximab Guide Dosing for Patients with Inflammatory Bowel Disease
Authors: Vande Casteele, Niels
Ferrante, Marc
Van Assche, Gert
Ballet, Vera
Compernolle, Griet
Van Steen, Kristel
Simoens, Steven
Rutgeerts, Paul
Gils, Ann #
Vermeire, Séverine # ×
Issue Date: Jun-2015
Publisher: W.B. Saunders
Series Title: Gastroenterology vol:148 issue:7 pages:1320-1329.e3
Article number: S0016-5085(15)00253-X
Abstract: Infliximab, a tumor necrosis factor antagonist, is effective for treating patients with Crohn's disease (CD) and ulcerative colitis (UC). We aimed to determine whether dosing based on therapeutic drug monitoring increases rate of remission and whether continued concentration-based dosing is superior to clinically based dosing of infliximab for maintaining remission in patients with CD and UC.
ISSN: 0016-5085
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Therapeutic and Diagnostic Antibodies (+)
Translational Research in GastroIntestinal Disorders
Department of Human Genetics - miscellaneous
Clinical Pharmacology and Pharmacotherapy
× corresponding author
# (joint) last author

Files in This Item:
File Description Status SizeFormat
Vande Casteele 2015_TAXIT.pdf Published 1681KbAdobe PDFView/Open Request a copy

These files are only available to some KU Leuven Association staff members


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science